We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04264936
Recruitment Status : Unknown
Verified February 2020 by Jun Guo, Peking University Cancer Hospital & Institute.
Recruitment status was:  Recruiting
First Posted : February 11, 2020
Last Update Posted : February 13, 2020
Information provided by (Responsible Party):
Jun Guo, Peking University Cancer Hospital & Institute

Brief Summary:
This is an open-label, single-arm, Phase Ib/II investigator-initiated trial of RC48-ADC combined with JS001 to evaluate the safety and pharmacokinetics of subjects with locally advanced or metastatic urothelial cancer

Condition or disease Intervention/treatment Phase
Urothelial Carcinoma Drug: RC48-ADC and JS001 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Open-label, Single-arm, Phase Ib/II Study of RC48-ADC and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer
Estimated Study Start Date : February 15, 2020
Estimated Primary Completion Date : January 30, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RC48-ADC and JS001 Drug: RC48-ADC and JS001
Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection

Primary Outcome Measures :
  1. Adverse events [ Time Frame: through study completion, an average of 1 year ]
    rate of adverse events

  2. maximal tolerated dose [ Time Frame: through study completion, an average of 1 year ]
    dose-limiting toxity

Secondary Outcome Measures :
  1. Peak Plasma Concentration(Cmax) [ Time Frame: through study completion, an average of 1 year ]
    Maximum observed plasma concentration

  2. Immunogenicity [ Time Frame: through study completion, an average of 1 year ]
    Numbers of participants with anti-drug antibody positive

  3. objective response rate [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first;assessed up to 60 months ]
    evaluated by RECIST 1.1 every 8 weeks

  4. the area under the curve (AUC) [ Time Frame: through study completion, an average of 1 year ]
    Area under the plasma concentration versus time curve

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent form; Aged 18 years and above; ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1; Life expectancy greater than 12 weeks; Patients with locally advanced or metastatic malignant urothelial carcinoma which is platinum naive and cisplatin ineligible, or progressed after at least one line standard systemic chemotherapy (including progression within 12 months of neo-/adjuvant therapy);

Cisplatinum ineligible patients should meet one of the following criteria:

  1. Aged 70 years and above, and ECOG performance is 1;
  2. Serum creatinine >= 1.0xULN or CrCl<60ml/min;
  3. Lose of hearing >= Grade 2;
  4. Peripheral nerve disorder >= Grade 2 Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Willing to provide primary lesion samples for the purpose of PD-L1 and HER2 tests.

Adequate organ function as defined by the following criteria:

  1. absolute neutrophil count(ANC) >= 1.5 x 10^9/L;
  2. platelets>=100* 10^9/L;
  3. Total serum creatinine <=1.5*ULN;
  4. serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=2.5*upper limit of normal (ULN), or AST and ALT<=5*ULN if liver function abnormalities are due to underlying malignancy; normal serum creatinine ;
  5. Left ventricular ejection fraction (LVEF) >=50%
  6. Hemoglobin>=9g/dl Women of child-bearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;

Exclusion Criteria:

  • Allergy to RC48-ADC, or JS001, or their components Received anti-cancer therapy including chemotherapy, radiotherapy, immunotherapy or other clinical trial treatments within 3 weeks of starting study treatment Unresolved toxicities from prior anti-cancer therapy, except for alopecia Previously treated with HER2-ADC and/or anti-PD-1 or anti-PD-L1 or anti PD-L2 therapies; Underwent major surgery within 4 weeks of first dose of study drug and not completely recovered; Received vaccine within 4 weeks of first dose of study drug Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or greater than or equal to Class 2 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the study; History of other neoplastic disease within 3 years prior to the study drug, with exception of resolved/curable cancers such as basal skin cancer or squamous cell skin cancer,.

Metastasis to CNS(central nervous system) and/or carcinomatous meningitis, with exception for the patients who received treatment of metastasis to CNS and/or carcinomatous meningitis and had stable disease for at least 3 months, and no evidence of progression within 4 weeks of first dose of study treatment. No evidence of new or expanded metastasis, and untreated with radiotherapy, surgery or steroid therapy within 4 weeks of first dose of study treatment.

History of allogeneic hematopoietic stem cell transplantation or organ transplantation; Patients who had received systemic steroid therapy within the last 2 years; Pregnancy or lactation; Positive results of HIV testing; Active HBV(hepatitis B virus) or HCV(hepatitis C virus) infection Active tuberculosis; Other disorders with clinical significance according to the researcher's judgment; Unwilling or unable to participate in all required study evaluations and procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04264936

Layout table for location contacts
Contact: xinan sheng, doctor. 010-88196348 doctor_sheng@126.com

Layout table for location information
China, Beijing
Beijing Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Contact: Jun Guo, MD    010-88121122    guoj307@126.com   
Sponsors and Collaborators
Peking University Cancer Hospital & Institute
Layout table for additonal information
Responsible Party: Jun Guo, Director, Peking University Cancer Hospital & Institute
ClinicalTrials.gov Identifier: NCT04264936    
Other Study ID Numbers: RC48-C014
First Posted: February 11, 2020    Key Record Dates
Last Update Posted: February 13, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type